Evidence map›Paper›PMID 29442524›Full record

Trial reportAmerican journal of respiratory and critical care medicine2018

Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.

Ken M Kunisaki, Mark T Dransfield, Julie A Anderson, Robert D Brook, Peter M A Calverley, Bartolome R Celli, Courtney Crim, Benjamin F Hartley, Fernando J Martinez, David E Newby and 5 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07481825 (Impact of Combined cARdio-pUlmonary aSsessment on COPD Clinical Management), which is not on this map. Cited by 195 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
195citing papers in PubMed, 13 pooled it
20.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07481825 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Impact of Combined cARdio-pUlmonary aSsessment on COPD Clinical Management: the ICARUS Study

TypeinterventionalSponsorUniversity of Bari Aldo MoroRan2026 to 2029Enrolled350ConditionsCOPD (Chronic Obstructive Pulmonary Disease), Cardiovascular DiseaseArmsStructured combined cardio-pulmonary clinical management strategy, Standard Respiratory Management
3 · Its place in the literature

Who cites it

195 citing papers in PubMed, 13 syntheses or guidelines pooled it, 344 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. The impact of body mass index on mortality in COPD: an updated dose-response meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2019
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Blood pressure response to exposure to moderate altitude in patients with COPD.International journal of chronic obstructive pulmonary disease · 2019
    Trial
  20. Trial

135 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Ken M Kunisaki1 Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota.ORCID 0000-0001-8644-2827
Mark T Dransfield3 Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama.
Julie A Anderson5 GlaxoSmithKline, Stockley Park, United Kingdom.
Robert D Brook6 University of Michigan, Ann Arbor, Michigan.
Peter M A Calverley7 University of Liverpool, Liverpool, United Kingdom.
Bartolome R Celli8 Brigham and Women's Hospital, Boston, Massachusetts.
Courtney Crim9 GlaxoSmithKline, Research Triangle Park, North Carolina.
Benjamin F Hartley10 Veramed Ltd., Twickenham, United Kingdom.
Fernando J Martinez11 Weill Cornell Medical College of Cornell University, New York, New York.
David E Newby12 University of Edinburgh, Edinburgh, United Kingdom; and.
Alexa A Pragman1 Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota.
Jørgen Vestbo13 University of Manchester, Manchester, United Kingdom.
Julie C Yates9 GlaxoSmithKline, Research Triangle Park, North Carolina.
Dennis E Niewoehner1 Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota.
SUMMIT Investigators
University of Minnesota System · USResearch Triangle Park Foundation · USBrigham and Women's Hospital · USCornell University · USGlaxoSmithKline (United Kingdom) · GBUniversity of Alabama at Birmingham · USUniversity of Edinburgh · GBUniversity of Liverpool · GBUniversity of Manchester · GBUniversity of Michigan · US

Funding

UAB Mentoring Program in COPD Patient Oriented ResearchK24HL140108 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DRANSFIELD, MARK T · 2018 to 2022
$439k
Evaluation of the Oral and Lung Microbiota and Inflammation in Chronic Obstructive Pulmonary Disease Frequent ExacerbatorsIK2CX001095 · VA · MINNEAPOLIS VA MEDICAL CENTER · PI PRAGMAN, ALEXA A · 2016 to 2021
–
CSRD VA IK2 CX001095NHLBI NIH HHS K24 HL140108
6 · The paper itself

Abstract

rationaleAcute exacerbations of chronic obstructive pulmonary disease (AECOPD) are common, associated with acute inflammation, and may increase subsequent cardiovascular disease (CVD) risk.

objectivesDetermine whether AECOPD events are associated with increased risk of subsequent CVD.

methodsWe performed a secondary cohort analysis of the SUMMIT (Study to Understand Mortality and Morbidity) trial, a convenience sample of current/former smokers with moderate COPD from 1,368 centers in 43 countries. All had CVD or increased CVD risk. AECOPD was defined as an increase in respiratory symptoms requiring treatment with antibiotics, systemic corticosteroids, and/or hospitalization. CVD events were a composite outcome of cardiovascular death, myocardial infarction, stroke, unstable angina, and transient ischemic attack. All CVD events were adjudicated. Cox proportional hazards models compared the hazard for a CVD event before AECOPD versus after AECOPD. MEASUREMENTS AND MAIN

resultsAmong 16,485 participants in SUMMIT, 4,704 participants had at least one AECOPD and 688 had at least one CVD event. The hazard ratio (HR) for CVD events after AECOPD was increased, particularly in the first 30 days after AECOPD (HR, 3.8; 95% confidence interval, 2.7-5.5) and was elevated up to 1 year after AECOPD. The 30-day HR after hospitalized AECOPD was more than twofold greater (HR, 9.9; 95% confidence interval, 6.6-14.9).

conclusionsIn patients with COPD with CVD or risk factors for CVD, exacerbations confer an increased risk of subsequent CVD events, especially in hospitalized patients and within the first 30 days after exacerbation. Patients and clinicians should have heightened vigilance for early CVD events after AECOPD. Clinical trial registered with www.clinicaltrials.gov (NCT 01313676).

Indexed as

AgedCohort StudiesDisease ProgressionFemaleHeart DiseasesHumansMaleMiddle AgedProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveRisk Factorscardiovascular diseaseschronic obstructive pulmonary diseasecohort study

Identifiers

PMID29442524
PMCPMC6913068
OpenAlexW2789802763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.